Muscle & Aging
Does BPC-157 Do Anything for Muscle?
The short answer
Almost everything known about BPC-157 and muscle comes from rats. A 2025 scoping review found human clinical studies of BPC-157 limited to three small pilot studies — covering knee pain, interstitial cystitis, and intravenous safety — and none of them tested muscle. A 2026 review of six emerging peptides found that two-thirds of all published musculoskeletal research on this compound class used animal models, mostly rats, and rated the human evidence as heterogeneous with 'modest improvements at best,' from studies that mostly lacked controls. In rats, transected quadriceps muscle healed faster and stronger with BPC-157 across a 72-day study. In people, no randomized controlled trial testing BPC-157 for muscle has been published.
Quick answers
- What is it?
- Whether BPC-157, a peptide compound, does anything for muscle healing or growth in humans.
- Why are people interested in it?
- BPC-157 is marketed to athletes and gym-goers for muscle recovery, and people want to know if there's actual human evidence behind it.
- What has actually been studied?
- A 2025 scoping review finding only three small human pilot studies of BPC-157 for any condition (none testing muscle), a 2026 review of six emerging peptides finding two-thirds of published research used animal models, and rat studies of transected quadriceps muscle healing over 72 days.
- How strong is the evidence?
- Animal research only for the muscle-specific question — no human trial has tested BPC-157 for a muscle outcome, so there is no direct human evidence in either direction.
- What don't we know yet?
- Whether BPC-157 has any effect on human muscle at all, what an effective or safe human dose would be, whether the rat mechanism (VEGF-driven angiogenesis) operates the same way in humans, why no sponsor has funded a proper human trial, and the actual risk profile at doses people use outside clinical settings.
- Where can I read the original research?
- Sources at the bottom of this page: McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing; Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
The short answer: Almost everything known about BPC-157 and muscle comes from rats, not people. A 2025 scoping review found the entire human clinical evidence base for BPC-157 limited to three small pilot studies — covering knee pain, interstitial cystitis, and intravenous safety — and none of them tested muscle. A 2026 review of six emerging peptides found two-thirds of all published musculoskeletal research on this compound class used animal models, and rated the available human evidence as heterogeneous with "modest improvements at best," drawn mostly from studies without controls. In rats, a fully transected quadriceps muscle healed faster and with better function over a 72-day study when treated with BPC-157. In humans, no randomized controlled trial testing BPC-157 for muscle has been published.
What the research shows
The animal literature is large, consistent, and entirely non-human
BPC-157 is a synthetic pentadecapeptide, a short 15-amino-acid fragment originally derived from a protein found in human gastric juice. It was first studied as an anti-ulcer agent, and over roughly two decades a single research group based mostly in Zagreb, Croatia, published a substantial body of work — almost all in rats — showing it accelerated healing across a wide range of tissue types: gastrointestinal ulcers and fistulas, skin, tendon, ligament, bone, corneal injury, and skeletal muscle.
The muscle-specific findings are consistent within that animal literature. In one study, researchers completely transected the quadriceps muscle in rats — a standard injury model that does not heal well on its own — and found that BPC-157, given by daily intraperitoneal injection, improved healing across every measure tracked over 72 days: biomechanical load-to-failure increased, walking recovery and motor function scores moved toward normal values, muscle fibers reconnected across the injury site, and the muscle's gross appearance approached that of uninjured tissue. A related study found BPC-157 could even reverse the muscle-healing impairment caused by systemic corticosteroid treatment in rats with crush injuries — a clinically relevant scenario, since corticosteroids are known to slow healing in real patients. A third mechanistic study linked these effects to increased VEGF expression and modulated angiogenesis (new blood vessel growth) in the healing muscle and tendon tissue of rats. A 2019 review summarizing this body of work concluded that BPC-157 has shown "consistently positive and prompt healing effects for various injury types" in animal models, while stating plainly that "the majority of studies have been performed on small rodent models and the efficacy of BPC-157 is yet to be confirmed in humans."
The human evidence is not just thin — it's almost nonexistent
Two independent 2025–2026 reviews quantified exactly how little human data exists. A 2025 scoping review in Current Reviews in Musculoskeletal Medicine identified "only three pilot studies" that have ever examined BPC-157 in humans, for any condition: one on intra-articular knee pain, one on interstitial cystitis, and one on intravenous safety and pharmacokinetics. The reviewers reported no adverse effects across these studies but were explicit that "rigorous, large-scale trials are lacking," and concluded that BPC-157 "should be considered investigational" until such trials exist.
A separate 2026 scoping review in The American Journal of Sports Medicine searched systematically for musculoskeletal research on BPC-157 alongside five other emerging peptides (TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu) and found that 67% of all identified publications used preclinical animal models, most commonly rats. Where human data existed at all, the reviewers described it as "heterogeneous" and revealing "modest improvements at best," coming from studies that mostly "lack[ed] robust controls or rigorous study designs." A third 2026 review specifically examining BPC-157 for orthopaedic and sports medicine use identified a single human case series of intra-articular knee injections, and flagged that it had "significant methodological flaws and a lack of controls" that limit how much can be concluded from it.
No trial has tested it for muscle specifically, in anyone
None of the three human pilot studies identified across these reviews tested BPC-157 for a muscle injury, muscle strength, or muscle mass outcome. The knee-pain case series involved joint injections, not muscle. The interstitial cystitis study addressed bladder pain. The intravenous study measured safety and pharmacokinetics, not a healing or performance endpoint. This means the specific claim this article set out to test — whether BPC-157 does anything for human muscle — currently has no direct human evidence to draw on in either direction. It is not that the studies found no effect; it is that the studies measuring a muscle-specific effect in humans do not appear to exist yet.
This matters because the animal data, however consistent, does not reliably predict human response. Rats and humans differ in muscle fiber composition, healing timelines, dosing pharmacokinetics, and injury mechanisms. A treatment that reliably accelerates healing in a rat's crushed gastrocnemius is not automatically assumed to do the same in a person's strained hamstring — that inference has to be tested, and for BPC-157 and muscle specifically, it has not been.
What we don't know yet
Whether BPC-157 has any effect on human muscle at all. No controlled human trial measuring a muscle-specific outcome — strength, cross-sectional area, injury recovery time — has been published, so there is no direct human evidence to confirm or rule out an effect.
What an effective or safe human dose would be. The rat studies used intraperitoneal or topical dosing scaled to rodent body weight; no dose-finding or pharmacokinetic study has established an equivalent human protocol for musculoskeletal use.
Whether the mechanism seen in rats — VEGF-driven angiogenesis and reduced inflammation — operates the same way in human tissue. This has not been directly tested.
Why the compound sold widely as a research chemical and supplement has not attracted a sponsor for a proper human trial, despite two decades of animal data and, according to reviewers, high public interest.
What the actual risk profile looks like at the doses people are using outside clinical settings. The three human pilot studies reported no adverse effects, but they involved small numbers of participants and short observation periods, which limits what can be concluded about rarer or longer-term risks.
Sources
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine, 2025;18(12):611-619. DOI
- Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. The American Journal of Sports Medicine, 2026. DOI
- Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine, 2026;54(1):223-229. DOI
- Yuan C, Demers A, Silva-Ortiz V, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International Journal of Molecular Sciences, 2026;27(6). DOI
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019;377(2):153-159. DOI
- Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of Orthopaedic Research, 2006;24(5):1109-1117. DOI
- Pevec D, Novinscak T, Brcic L, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical Science Monitor, 2010;16(3):BR81-88. PMID: 20190676
- Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology, 2009;60(Suppl 7):191-196. PMID: 20388964
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Energy & Performance · Aging & Longevity | Evidence Index: bpc-157
Sources
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
- Current Reviews in Musculoskeletal Medicine, 2025 · DOI
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine
- The American Journal of Sports Medicine, 2026 · DOI
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- The American Journal of Sports Medicine, 2026 · DOI
- From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management
- International Journal of Molecular Sciences, 2026 · DOI
- Gastric Pentadecapeptide Body Protection Compound BPC 157 and Its Role in Accelerating Musculoskeletal Soft Tissue Healing
- Cell and Tissue Research, 2019 · DOI
- Effective Therapy of Transected Quadriceps Muscle in Rat: Gastric Pentadecapeptide BPC 157
- Journal of Orthopaedic Research, 2006 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.